Changes in Neuropsychiatric Inventory Associated with Semagacestat Treatment of Alzheimer's Disease.

导出原文传递

翻译打印收藏纠错

作者： Paul B,Rosenberg ^[1] ; Krista L,Lanctôt ^[2] ; Nathan,Herrmann ^[3] ; Jacobo E,Mintzer ^[4] ; Anton P,Porsteinsson ^[5] ; Xiaoying,Sun ^[6] ; Rema,Raman ^[7]

作者单位： Department of Psychiatry and Behavioral Sciences, Division of Geriatric Psychiatry and Neuropsychiatry, Johns Hopkins School of Medicine, Baltimore, MD, USA. ^[1] Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, ON, Canada. ^[2] Departments of Psychiatry and Pharmacology/Toxicology, University of Toronto, Toronto, ON, Canada. ^[3] Division of Geriatric Psychiatry, Sunnybrook Health Sciences Centre, Toronto, ON, Canada. ^[4] Department of Psychiatry, Division of Geriatric Psychiatry, University of Toronto, Toronto, ON, Canada. ^[5] Roper St. Francis Clinical Biotechnology Research Institute, Charleston, SC, USA. ^[6] Ralph H. Johnson Veterans Affairs Medical Center, Charleston, SC, USA. ^[7] Medical University of South Carolina, Charleston, SC, USA. ^[8] School of Internal Medicine, University of South Carolina, Columbia, SC, USA. ^[9] Department of Psychiatry, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA. ^[10] Biostatistics Research Center, University of California, San Diego, La Jolla, CA, USA. ^[11] Alzheimer's Therapeutic Research Institute (ATRI), Keck School of Medicine of USC, University of Southern California, Los Angeles, CA, USA. ^[12]

关键词 Alzheimer’s disease amyloid clinical trial depression neuropsychiatry